Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 25, Issue 2, Pages 109-118Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612825666190312110836
Keywords
Doxorubicin; cardiotoxicity; nanotechnology; phytochemicals; probiotics; cardioprotective agents
Categories
Funding
- Fundacao de Amparo a Pesquisa do Estado de Goias, FAPEG [200910267000417, 201210267001027, 201710267000068, SES-GO/CNPq/MS-DECIT/2017 - PPSUS/GO - 201710267001251]
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq [481457/2013-5, 303308/2013-3]
Ask authors/readers for more resources
Doxorubicin (DOX) is a cytostatic antibiotic from the class of anthracyclines widely used in chemotherapeutic cancer treatments. Despite the efficiency against several types of cancer, the use of DOX remains limited due to the side effects, especially cardiotoxicity. Among the DOX administration strategies, there are the classic players such as nanoparticles and polymers, which are capable of DOX delivery directly to interesting neoplastic regions. On the other hand, the new players such as phytochemicals and probiotics emerged with the proposal to react with DOX free radicals, reducing the oxidative stress, inflammatory and apoptotic process. Thus, this review aims to report the studies involving these classics and new players along the years that focus on improved administration and reduction of DOX-induced cardiotoxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available